Local ablation or radioembolization of colorectal cancer metastases: comorbidities or older age do not affect overall survival
Open Access
- 10 September 2018
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 882
Abstract
Background: Local ablative techniques are emerging in patients with oligometastatic disease from colorectal carcinoma, commonly described as less invasive than surgical methods. This single arm cohort seeks to determine whether such methods are suitable in patients with comorbidities or higher age. Methods: Two hundred sixty-six patients received radiofrequency ablation (RFA), CT-guided high-dose rate brachytherapy (HDR-BT) or Y90-radioembolization (Y90-RE) during treatment of metastatic colorectal cancer (mCRC). This cohort comprised of patients with heterogenous disease stages from single liver lesions to multiple organ systems involvement commonly following multiple chemotherapy lines. Data was reviewed retrospectively for patient demographics, previous therapies, initial or disease stages at first intervention, comorbidities and mortality. Comorbidity was measured using the Charlson Comorbidity Index (CCI) and age-adjusted Charlson Index (CACI) excluding mCRC as the index disease. Kaplan-Meier survival analysis and Cox regression were used for statistical analysis. Results: Overall median survival of 266 patients was 14 months. Age >= 70 years did not influence survival after local therapies. Similarly, CCI or CACI did not affect the patients prognoses in multivariate analyses. Moderate or severe renal insufficiency (n = 12; p = 0.005) was the only single comorbidity identified to negatively affect the outcome after local therapy. Conclusion: Interventional procedures for mCRC may be performed safely even in elderly and comorbid patients. In severe renal insufficiency, the use of invasive techniques should be limited to selected cases.Keywords
This publication has 38 references indexed in Scilit:
- The role of image-guided therapy in the management of colorectal cancer metastatic diseaseEuropean Journal of Cancer, 2017
- Y90 Radioembolization in chemo-refractory metastastic, liver dominant colorectal cancer patients: outcome assessment applying a predictive scoring systemBMC Cancer, 2016
- Radioembolization as a Treatment Strategy for Metastatic Colorectal Cancer to the Liver: What Can We Learn from the SIRFLOX Trial?Current Treatment Options in Oncology, 2016
- Effect of heat sink on the recurrence of small malignant hepatic tumors after radiofrequency ablationJournal of Cancer Research and Therapeutics, 2016
- The Impact of Age on Colorectal Cancer Incidence, Treatment, and Outcomes in an Equal-Access Health Care SystemDiseases of the Colon & Rectum, 2014
- Chemotherapy compliance, tolerance and efficacy in elderly and non-elderly patients with metastatic colorectal cancer: a single institution comparative study.2013
- Rates and predictors of chemotherapy use for stage III colon cancerCancer, 2008
- Never Too Old? Age Should Not Be a Barrier to Enrollment in Cancer Clinical TrialsThe Oncologist, 2005
- Liver Malignancies: CT-Guided Interstitial Brachytherapy in Patients with Unfavorable Lesions for Thermal AblationJournal of Vascular and Interventional Radiology, 2004
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994